Depression

The CRF hypothesis of depression, formalized by Charles Nemeroff and colleagues, proposes that sustained CRF hyperactivity drives the HPA axis hyperactivation, sleep disruption, appetite changes, psychomotor alterations, and anxiety observed in major depressive disorder (Nemeroff et al., 1984). Supporting evidence includes elevated CSF CRF in depressed patients, blunted ACTH response to exogenous CRF (indicating pituitary CRF1R downregulation from chronic CRF exposure), and normalization of CSF CRF levels with successful antidepressant treatment.

CRF1 Receptor Antagonists

The development of CRF1R antagonists represents a major translational effort in psychiatry:

• Antalarmin: Early non-peptide CRF1R antagonist that reduces anxiety-like behavior in primates and rodents (Habib et al., 2000). Limited by poor pharmacokinetics for human use.
• Pexacerfont (BMS-562086): Advanced to Phase III clinical trials for generalized anxiety disorder but failed to separate from placebo, dampening industry enthusiasm for the CRF1R antagonist class (Coric et al., 2010).
• Verucerfont (GSK561679): Showed some efficacy in stress-induced alcohol craving in women with PTSD comorbidity, suggesting potential in specific patient subpopulations rather than broad anxiety disorders.

The clinical failure of CRF1R antagonists in broad psychiatric populations has been a significant setback, though renewed interest focuses on biomarker-stratified subpopulations with documented CRF hyperactivity.

PTSD

CRF signaling is prominently dysregulated in PTSD. CSF CRF levels are significantly elevated in combat veterans with PTSD compared to healthy controls (Baker et al., 1999). CRF circuits in the amygdala and BNST are critical for fear memory consolidation and the exaggerated startle response characteristic of PTSD. CRF1R antagonists have been investigated for PTSD, with verucerfont showing preliminary signals in reducing stress-potentiated fear responses.

Addiction

CRF signaling in the extended amygdala (central amygdala, BNST, nucleus accumbens shell) mediates the negative emotional state associated with drug withdrawal, which drives compulsive drug-seeking behavior (Koob, 2008). CRF1R antagonists reduce stress-induced reinstatement of drug-seeking for alcohol, cocaine, heroin, and nicotine in preclinical models. George Koob's allostatic model of addiction positions CRF as the key neurochemical mediator of the "dark side" of addiction — the transition from positive reinforcement to negative reinforcement (drug taking to relieve withdrawal distress).

Irritable Bowel Syndrome (IBS)

CRF is a major mediator of stress-induced GI dysfunction. CRF receptors are expressed throughout the enteric nervous system, and CRF administration increases colonic motility, visceral pain sensitivity, and intestinal permeability — all features of IBS (Taché & Bonaz, 2007). CRF1R activation stimulates colonic motility and secretion, while CRF2R activation inhibits gastric emptying. Peripheral CRF1R antagonists have shown efficacy in reducing stress-induced diarrhea and visceral hypersensitivity in preclinical models and early clinical trials.

Anxiety and Fear

CRF is one of the most extensively studied anxiogenic neuropeptides. Central administration of CRF in rodents produces a constellation of anxiety-like behaviors: decreased exploration, enhanced startle, increased freezing, and suppressed social interaction (Dunn & Berridge, 1990). These effects are mediated primarily by CRF1R in the central amygdala and BNST. CRF-overexpressing transgenic mice display chronic anxiety-like phenotypes, while CRF1R knockout mice show reduced anxiety responses to stress.

In humans, cerebrospinal fluid CRF concentrations are elevated in patients with major depression, PTSD, and anxiety disorders, correlating with symptom severity (Nemeroff et al., 1984). Postmortem studies of depressed suicide victims show upregulated CRF expression in the PVN and downregulated CRF1R in frontal cortex (consistent with chronic CRF hypersecretion).

Adrenal Insufficiency Assessment

CRH testing plays a role in evaluating secondary and tertiary adrenal insufficiency:

• Secondary (pituitary): Blunted ACTH response to CRH with low baseline cortisol
• Tertiary (hypothalamic): Delayed but eventually normal ACTH response to exogenous CRH, reflecting an intact pituitary that has been understimulated
• Post-glucocorticoid withdrawal: CRH testing can assess recovery of the HPA axis after chronic exogenous glucocorticoid suppression

CRH Stimulation Test

The CRH stimulation test is a key clinical diagnostic tool (Nieman et al., 1986)):

• Protocol: IV injection of ovine CRH (1 μg/kg) or human CRH (100 μg fixed dose), with serial ACTH and cortisol measurements at -15, 0, 15, 30, 45, 60, 90, and 120 minutes
• Cushing's disease (pituitary): Exaggerated ACTH and cortisol response (>35-50% increase over baseline)
• Ectopic ACTH syndrome: Blunted or absent ACTH response to CRH (tumor ACTH secretion is autonomous)
• Primary adrenal Cushing's: Suppressed ACTH at baseline, no response to CRH
• Inferior petrosal sinus sampling (IPSS) with CRH: Gold standard for differentiating pituitary from ectopic ACTH sources. Central-to-peripheral ACTH ratio >3:1 after CRH = pituitary source

Placental CRH

Placental CRH production is unique to primates and represents one of the most dramatic endocrine changes in pregnancy (McLean et al., 1995):

• Exponential increase: Placental CRH rises exponentially from mid-gestation, reaching maternal plasma levels 1000-fold above non-pregnant values by term
• Positive feedback: Unlike hypothalamic CRH (suppressed by cortisol), placental CRH expression is stimulated by cortisol, creating a positive feed-forward loop that amplifies CRH production as pregnancy progresses
• Placental clock hypothesis: The rate of placental CRH rise predicts gestational length — women who deliver preterm have earlier and steeper CRH elevations, leading to the concept of a "placental clock" timing parturition
• CRH-binding protein: Maternal CRH-BP levels fall sharply in the final weeks of pregnancy, releasing bound CRH and increasing bioactive CRH at the onset of labor

CRH in Inflammatory Conditions

CRH has significant immunomodulatory functions beyond the HPA axis (Chrousos, 1995):

• Peripheral CRH: Immune cells (macrophages, lymphocytes, mast cells) and inflamed tissues express CRH locally. Peripheral CRH acts in a paracrine fashion to modulate inflammation, often with pro-inflammatory effects distinct from the immunosuppressive action of HPA-axis-derived cortisol
• Mast cell activation: CRH activates mast cell degranulation, increasing vascular permeability and promoting neurogenic inflammation
• Inflammatory bowel disease: Colonic CRH expression is elevated in ulcerative colitis and Crohn's disease, contributing to mucosal inflammation and altered motility
• Rheumatoid arthritis: Synovial CRH expression is increased in inflamed joints, though its net effect (pro- vs. anti-inflammatory) depends on the balance with local cortisol production
• Skin inflammation: CRH and CRF1R are expressed in skin, where they modulate keratinocyte proliferation, mast cell activation, and cutaneous inflammation

CRH Family Members

The CRH peptide family includes three urocortins (Bale & Vale, 2004):

• Urocortin 1: Binds both CRF1R and CRF2R with high affinity. Involved in stress responses, appetite suppression, and cardioprotection
• Urocortin 2 (stresscopin-related peptide): Selective CRF2R agonist. Mediates stress coping, cardiovascular regulation, and metabolic effects
• Urocortin 3 (stresscopin): Selective CRF2R agonist. Involved in stress recovery, insulin secretion, and energy balance